Summary & Overview
HCPCS G9128: Multiple Myeloma Disease Status Assessment, Smoldering/Stage I
HCPCS Level II code G9128 designates a disease status assessment for patients with multiple myeloma or systemic disease limited to smoldering and Stage I presentations, intended for use within a Medicare-approved demonstration project. Nationally, this code matters because it codifies a narrowly defined oncology assessment in a programmatic research or demonstration context, affecting how participating providers document early-stage multiple myeloma monitoring and how payers recognize demonstration-based services.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical scope and service setting, guidance on which payers are relevant to coverage discussions, and context for how the code fits into oncology disease-status reporting for early multiple myeloma. The publication outlines expected benchmarks for code use, summarizes applicable policy or demonstration program considerations, and situates the code within outpatient oncology practice patterns. Data not available in the input is clearly identified where applicable.
Billing Code Overview
HCPCS Level II code G9128 represents a disease status assessment specifically for multiple myeloma and related systemic disease presentations, limited to smoldering and Stage I disease. The code description indicates use within a Medicare-approved demonstration project, signaling restricted clinical and programmatic application.
-
Service type: Disease status assessment for oncology patients with multiple myeloma or systemic disease in smoldering or Stage I presentations
-
Typical site of service: Oncology clinics, outpatient infusion or hematology/oncology specialty centers, and settings participating in Medicare demonstration projects
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with laboratory and bone marrow findings consistent with smoldering multiple myeloma (SMM) presents to a tertiary oncology clinic enrolled in a Medicare-approved demonstration project assessing disease status monitoring. The patient is asymptomatic with no CRAB criteria (hyperCalcemia, Renal dysfunction, Anemia, Bone lesions) and falls into Stage I disease based on standard staging criteria. The clinical workflow includes a hematology/oncology visit for disease status assessment, review of recent serum protein electrophoresis, free light chain assay, complete blood count, metabolic panel, and periodic bone imaging when indicated. The oncology clinician documents disease status (stable, progressing, or transformation to active myeloma) and determines ongoing monitoring frequency consistent with the demonstration project protocol. Billing uses the HCPCS Level II code G9128 for reporting oncology disease status limited to multiple myeloma, smoldering, Stage I, within the Medicare demonstration. Typical site of service is an outpatient oncology clinic or hospital outpatient department affiliated with the demonstration project. Common accompanying activities include laboratory specimen collection, review of diagnostic testing results, multidisciplinary discussion, and documentation of disease status in the electronic health record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) |